doi: 10.1111/obr.12970
Requiring Certain Manufacturers To Report Drug Pricing Information for Part B ( 414.802 and 414.902) In the CY 2022 PFS final rule, it was stated that the new provisions finalized in that rule at 414.802 and 414.804 implemented new statutory requirements under sections 1847A and 1927 of the Act, as amended by section 401 of Division CC, Title IV of the CAA, 2021 (for the purposes of this section of this proposed rule, hereinafter is referred to as section 401), which requires manufacturers without a Medicaid National Drug Rebate Agreement (NDRA) to report ASP information to CMS for calendar quarters beginning on January 1, 2022, for drugs or biologicals payable under Medicare Part B and described in sections 1842(o)(1)(C), (E), or (G) or 1881(b)(14)(B) of the Act, including items, services, supplies, and products that are payable under Part B as a drug or biological (86 FR 65560)
These compounds have a strong odor that we detect at tiny concentrations
Many people also report that alcohol worsens nausea for a day or two afterward
Motivated to make a change, Bartels went to a doctor for tirzepatide the active ingredient in GLP-1 drugs like Zepbound and Mounjaro which mimics natural gut hormones to curb appetite, lower blood sugar and boost feelings of fullness
